PMS1

Across TCGA pan-cancer cohorts, PMS1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PMS1 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PMS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PMS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUAD, UCEC, and BRCA are the cancer types where PMS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.004	0.662	<.001	18	view →
UCEC	DFS	Median	All	0.959	0.619	.016	10	view →
BRCA	OS	Median	II,III,IV	0.792	0.958	.007	8	view →
COAD	OS	Median	III,IV	0.163	0.791	.004	6	view →
BLCA	OS	Median	All	1.000	0.416	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PMS1–LUAD (OS)

Open the LUAD breakdown →